StockDuty ← Dashboard Sep 14, 2026 11:07 PM ET
SignalFDA/Bio

BIONTECH LUNG CANCER DRUG EXTENDS SURVIVAL VERSUS CHEMOTHERAPY - JAPAN_TIMES

BioNTech lung cancer drug extends survival versus chemotherapy, a key clinical catalyst.

BioNTech lung cancer drug extends survival versus chemotherapy, a key clinical catalyst.
BioNTech lung cancer drug extends survival versus chemotherapy, a key clinical catalyst. — impact context not separately stored; see What changed.
Sources